Ginkgo Bioworks Holdings Inc vs Erasca Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.73 (market cap $763.64M), while Erasca Inc. Common Stock trades at $15.64 (market cap $5.40B). The key difference: Erasca Inc. Common Stock is far larger — about 7.1× Ginkgo Bioworks Holdings Inc's market cap, and Erasca Inc. Common Stock is more actively traded (9,533,185 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Erasca Inc. Common Stock for 0 Days on average.
| DNA | ERAS | |
|---|---|---|
Market Cap | $763.64M | $5.40B |
Volume | 3,204,177 | 9,533,185 |
Sector | Health | Health |
52-Week High | $15.83 | $22.47 |
52-Week Low | $5.48 | $2.20 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $865.59M | $5.18B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →